NCT03936959 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03936959
Title	A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Eli Lilly and Company
Indications	biliary tract cancer malignant mesothelioma anus cancer Merkel cell carcinoma ovarian cancer stomach cancer endometrial cancer lung non-small cell carcinoma Advanced Solid Tumor lung small cell carcinoma transitional cell carcinoma skin squamous cell carcinoma nasopharynx carcinoma hepatocellular carcinoma breast cancer prostate cancer cervical cancer colorectal cancer thyroid cancer melanoma salivary gland cancer esophageal cancer head and neck squamous cell carcinoma
Therapies	LY3434172
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| BEL \| AUS

Facility	City	State	Zip	Country	Details
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	United States	Details
St Vincent's Hospital	Sydney	New South Wales	2010	Australia	Details
Universitair Ziekenhuis Gent	Ghent		9000	Belgium	Details
Institut Claudius Regaud - IUCT Oncopole	Toulouse		31059	France	Details
Asan Medical Center	Songpa-gu	Seoul	05505	South Korea	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03936959Clinical Trial Detail